Results 41 to 50 of about 53,103 (125)

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]

, 2009
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
Holyoake, T., Tessa Holyoake, Michor Franziska, Michor, F., Holyoake Tessa, Clarkson Bayard, Foo, J., Mark W Drummond, Franziska Michor, Bayard Clarkson, Foo Jasmine, Drummond, M.W., Jasmine Foo, Clarkson, B., Drummond Mark W.   +14 more
core   +2 more sources

Elucidating the role of the tumor suppressor Protein Phoshatase 2A in Chronic Myeloid Leukemia. [PDF]

, 2010
Protein phosphatase-2A (PP2A) is one of the major cellular serine-threonine phosphatases and is involved in the regulation of cell homeostasis through the negative regulation of signaling pathways initiated by protein kinases.
Neviani, Paolo
core  

2025 ACVIM Forum Research Abstract Program

Journal of Veterinary Internal Medicine, Volume 39, Issue 6, November/December 2025.
wiley   +1 more source

Breakthrough in the treatment of chronic myeloid leukemia [PDF]

, 2012
Chronic myeloid leukemia (CML) was once a life-threatening disease in which the clonal expansion of leukemic myeloid cells occurs as a result of reciprocal chromosomal translocation between long arm of chromosome 9 and 22 (Philadelphia chromosome).
Yamada, Yoshihiro
core  

Immunocytochemistry.

, 2013
Immunocytochemistry.
Weiya Z. Wysham (335681), Suzanna Syriac (335683), Laura Hays (335682), Hong Li (20183), Tijana Skrepnik (335684), Nupur Pande (335686), Tanja Pejovic (241749), Paulette Mhawech-Fauceglia (226809), Maureen Hoatlin (335688), Jay Wright (335685)   +9 more
core   +1 more source

Morphological and immunophenotipic characterization of canine lymphoma in liquid based cytology and cell block immunocytochemistry

, 2016
O linfoma canino é uma das neoplasias mais prevalentes em cães, diagnosticado frequentemente através de exame citológico de aspirados. A imunofenotipagem para diferenciação entre linfomas de células B e T é importante para definição prognóstica e ...
Fernandes, Natália Coelho Couto de Azevedo
core   +1 more source

UNLEASHING THE POWER OF CML THE JOURNEY TO EKSA AWARD [PDF]

21 February 2024 - The Public Sector Conducive Ecosystem, better known as EKSA, is a rebranding exercise of Public Sector 5S practice. The initiative aims to strengthen the organisational culture of high performance and innovation among public sector ...
Hanisah, Kasbon, Fathiah Izzati, Mohammad Fadzillah   +1 more
core   +2 more sources

Plenary Abstracts Session & Oral Presentations

HemaSphere, Volume 9, Issue S1, June 2025.
wiley   +1 more source

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.

, 2001
Achieving a complete cytogenetic response (CCgR) is a major target in the treatment of chronic myeloid leukemia (CML) with interferon-alpha (IFN-alpha), but CCgRs are rare. The mean CCgR rate is 13%, in a range of 5% to 33%.
A. Hochhaus, F. Guilhot, Swedish Cml Study Group, J. L. Steegmann, J. Hasford, E. Trabacchi, F. X. Mahon, O. F. Cml France Intergroup, Spanish Cml Study Group, G. Martinelli, A. Louwagie, S. Tura, U. K. Medical Research Council Working Party On Cml, F. Bonifazi, A. De Vivo, J. Reiffers, Italian Cooperative Study Group On Cml, German Cml Study Group, S. Saglio, European Study Group On Interferon In Chronic Myeoloid Leukemia, P. C. Shepherd, R. Hehlman, J. Thaler, ALIMENA, Giuliana, B. Simonsson, G. Rosti, N. Testoni, H. C. Kluin Nelemans, Australian Cml Study Group, E. Montefusco, M. Baccarani   +30 more
core   +1 more source

Publication Only

HemaSphere, Volume 9, Issue S1, June 2025.
wiley   +1 more source